Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer’s disease

Alzheimer’s disease (AD) is an age-related neurodegenerative disorder associated with progressive memory loss, severe dementia, and hallmark neuropathological markers, such as deposition of amyloid-β (Aβ) peptides in senile plaques and accumulation of hyperphosphorylated tau proteins in neurofibrillary tangles. Recent evidence obtained from transgenic mouse models suggests that soluble, nonfibrillar Aβ oligomers may induce synaptic failure early in AD. Despite their undoubted value, these transgenic models rely on genetic manipulations that represent the inherited and familial, but not the most abundant, sporadic form of AD. A nontransgenic animal model that still develops hallmarks of AD would be an important step toward understanding how sporadic AD is initiated. Here we show that starting between 12 and 36 mo of age, the rodent Octodon degus naturally develops neuropathological signs of AD, such as accumulation of Aβ oligomers and phosphorylated tau proteins. Moreover, age-related changes in Aβ oligomers and tau phosphorylation levels are correlated with decreases in spatial and object recognition memory, postsynaptic function, and synaptic plasticity. These findings validate O. degus as a suitable natural model for studying how sporadic AD may be initiated.

[1]  A. Kirkwood,et al.  Consequences of Inhibiting Amyloid Precursor Protein Processing Enzymes on Synaptic Function and Plasticity , 2012, Neural plasticity.

[2]  M. Mattson,et al.  Ceruloplasmin deficiency results in an anxiety phenotype involving deficits in hippocampal iron, serotonin, and BDNF , 2012, Journal of neurochemistry.

[3]  S. Lesné,et al.  Soluble Aβ oligomer production and toxicity , 2012, Journal of neurochemistry.

[4]  P. Sachdev,et al.  Recent rodent models for Alzheimer’s disease: clinical implications and basic research , 2012, Journal of Neural Transmission.

[5]  K. Ashe,et al.  Cognitive effects of cell-derived and synthetically derived Aβ oligomers , 2011, Neurobiology of Aging.

[6]  M. Caballero-Bleda,et al.  Age-related brain pathology in Octodon degu: Blood vessel, white matter and Alzheimer-like pathology , 2011, Neurobiology of Aging.

[7]  Julie R. Leitz,et al.  Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation , 2011, The Journal of Neuroscience.

[8]  E. Mandelkow,et al.  Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.

[9]  S. Ferreira,et al.  Amyloid-β Peptide Oligomers Disrupt Axonal Transport through an NMDA Receptor-Dependent Mechanism That Is Mediated by Glycogen Synthase Kinase 3β in Primary Cultured Hippocampal Neurons , 2010, The Journal of Neuroscience.

[10]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[11]  W. Klein,et al.  Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5 , 2010, Neuron.

[12]  G. Bernardi,et al.  Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer's disease. , 2010, Learning & memory.

[13]  L. Lannfelt,et al.  Animal models of amyloid‐β‐related pathologies in Alzheimer’s disease , 2010, The FEBS journal.

[14]  C. Robinson,et al.  Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. , 2009, Nature chemistry.

[15]  T. Südhof,et al.  Presenilins are Essential for Regulating Neurotransmitter Release , 2009, Nature.

[16]  G. Zamponi Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. , 2009 .

[17]  Zhen Yan,et al.  β-Amyloid Impairs AMPA Receptor Trafficking and Function by Reducing Ca2+/Calmodulin-dependent Protein Kinase II Synaptic Distribution* , 2009, Journal of Biological Chemistry.

[18]  Pedro Pesini,et al.  Natural Non-Trasgenic Animal Models for Research in Alzheimer’s Disease , 2009, Current Alzheimer research.

[19]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[20]  M. Memo,et al.  Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways , 2009, Amino Acids.

[21]  D. Selkoe,et al.  Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior , 2008, Behavioural Brain Research.

[22]  A. Kirkwood,et al.  Potential Adaptive Function for Altered Long-Term Potentiation Mechanisms in Aging Hippocampus , 2008, The Journal of Neuroscience.

[23]  J. Götz,et al.  Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.

[24]  L. Mucke,et al.  Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models* , 2007, Journal of Biological Chemistry.

[25]  W. Klein,et al.  Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.

[26]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[27]  J. Ting,et al.  Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms , 2007, Proceedings of the National Academy of Sciences.

[28]  W. Klein,et al.  Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[29]  Kimberly Scearce-Levie,et al.  Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. , 2007, The Journal of biological chemistry.

[30]  F. LaFerla,et al.  Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles* , 2006, Journal of Biological Chemistry.

[31]  D. Selkoe,et al.  Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.

[32]  Mark Bowlby,et al.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[34]  K. Krause,et al.  Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease? , 2006, Genes, brain, and behavior.

[35]  Eric H. Chang,et al.  AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[37]  A. Kirkwood,et al.  NMDA receptor–independent long-term depression correlates with successful aging in rats , 2005, Nature Neuroscience.

[38]  P. Greengard,et al.  Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses , 2005, Neurobiology of Disease.

[39]  F. Aboitiz,et al.  Human-like rodent amyloid-β-peptide determines Alzheimer pathology in aged wild-type Octodon degu , 2005, Neurobiology of Aging.

[40]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[41]  C. Finch,et al.  Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.

[42]  K. Duff,et al.  Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? , 2004, Briefings in functional genomics & proteomics.

[43]  V. Bigl,et al.  Guinea Pigs as a Nontransgenic Model for APP Processing in Vitro and in Vivo , 2003, Neurochemical Research.

[44]  C. Finch,et al.  Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[45]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[46]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[47]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[48]  C. Barnes,et al.  Impact of aging on hippocampal function: plasticity, network dynamics, and cognition , 2003, Progress in Neurobiology.

[49]  D. Peterson,et al.  Evidence That Synaptically Released β-Amyloid Accumulates as Extracellular Deposits in the Hippocampus of Transgenic Mice , 2002, The Journal of Neuroscience.

[50]  J. Dodart,et al.  Does my mouse have Alzheimer's disease? , 2002, Genes, brain, and behavior.

[51]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[52]  Satish K. Sharma,et al.  Direct interaction of soluble human recombinant tau protein with Aβ 1–42 results in tau aggregation and hyperphosphorylation by tau protein kinase II , 2002, FEBS letters.

[53]  G. Collingridge,et al.  Age-Related Impairment of Synaptic Transmission But Normal Long-Term Potentiation in Transgenic Mice that Overexpress the Human APP695SWE Mutant Form of Amyloid Precursor Protein , 2001, The Journal of Neuroscience.

[54]  C. Finch,et al.  Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.

[55]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[56]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Pavia,et al.  Alzheimer's disease: relationship between muscarinic cholinergic receptors, β‐amyloid and tau proteins , 1998, Fundamental & clinical pharmacology.

[58]  E. Vanmechelen,et al.  Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205 , 1995, Neuroscience Letters.

[59]  M. Goedert,et al.  Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404 , 1994, Journal of neuroscience research.

[60]  A. Radulska,et al.  Object recognition is not impaired in old rats. , 1994, Acta neurobiologiae experimentalis.

[61]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[62]  S. Little,et al.  Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. , 1991, Brain research. Molecular brain research.

[63]  J. Delacour,et al.  Short-term memory, exploration and locomotor activity in aged rats , 1987, Neurobiology of Aging.